Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Are you interested in learning about the skills needed to commercialize an innovation? Do you have an innovation that you are looking to bring out of the lab? Are you looking for funding to aide commercialization efforts? Attend the LIBH Commercialization Workshop.
The Long Island Bioscience Hub (LIBH) is hosting a Life Science focused Mini-Boot Camp- a one day rapid fire workshop that will provide practical tools used in commercialization as well as strategies to enhance applications for LIBH grant funding.
Thursday, October 29, 2015
8:30a-3:00pLong Island High Technology Incubator
25 Health Sciences Drive, Stony Brook, NY 11794
Who Should Attend: Faculty, Physicians, Fellows, Post Docs, Grad Students
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2275
[post_author] => 3
[post_date] => 2016-06-22 14:40:28
[post_date_gmt] => 2016-06-22 14:40:28
[post_content] =>
The Center for Biotechnology team recently ventured out to San Francisco for BIO’s annual International Convention. Through the support of Empire State Development and the Long Island Bioscience Hub, the Center for Biotechnology was able to support six Long Island emerging biotech companies to attend the meeting: Alpha-1 Biologics Corporation, Codagenix, Inc., DepYMed, Inc., iCell Gene Therapeutics, PhD Skin Care LLC and Vela Therapeutics. These companies were joined in the New York Pavilion by more than two dozen other companies and entities representing New York State.
Long Island and New York City regional companies Alpha-1 Biologics, Vela Therapeutics, Intrommune Therapeutics, PainQX, Serendipity Biotech, ENB Therapeutics, and QuickSilver Biosystems all were recipients of grants from Empire State Development and NewYorkBio which also assisted their participation in the event. These companies were tapped to present in the New York Pavilion along with six other companies from upstate New York.
Envisagenics, ENB Therapeutics, PainQx, QuickSilver and Abcombi BioSciences, all New York State Companies, were invited to participate in the BIO 2016 “Start-Up Stadium” which provide start-up companies with the opportunity to pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. The participating investors provided live feedback and judged the sessions.
In addition, six Long Island Bioscience Hub faculty members were invited to participate in the meeting for the first time. These NIH-REACH program supported faculty attended with the goal to learn more about the commercialization process, how it applies to their translational research, and to engage in the partnering process and meet with potential strategic contacts. Center staff met with over 40 strategic partners over the course of the meeting and follow up is underway.
[post_title] => BIO 2016
[post_excerpt] => The Center for Biotechnology team recently attended the BIO International Convention in San Francisco and supported the participation of emerging companies and faculty entrepreneurs in the event.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bio-international-convention-2016
[to_ping] =>
[pinged] =>
[post_modified] => 2016-07-14 13:50:46
[post_modified_gmt] => 2016-07-14 13:50:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2275
[menu_order] => 175
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4495
[post_author] => 4
[post_date] => 2024-11-06 09:37:46
[post_date_gmt] => 2024-11-06 14:37:46
[post_content] =>
America’s Seed Fund, also known as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program, offers small business entrepreneurs in the life sciences more than $1.4 billion in non-dilutive funding to support small business research and development.
Join NIH SEED for this informational webinar on Wednesday, November 13, at 1:00 p.m. ET, where you’ll learn about open funding opportunities, common application errors, and how to avoid them.
Bring your questions - there will be a live Q&A session following the presentation! Next receipt date is January 5.
Speaker: Stephanie Fertig, Director, NIH Small Business Program
Moderator: Adam Sorkin, NIH Small Business Policy Manager
REGISTER HERE Can’t make it? The webinar will be recorded and posted online about 7 business days after the event.
[post_title] => Webinar: NIH’s Seed Fund - Submitting Successfully to the Small Business Program
[post_excerpt] => learn about open SBIR & STTR funding opportunities, common application errors, and how to avoid them.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => webinar-nihs-seed-fund-submitting-successfully-to-the-small-business-program
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:46:15
[post_modified_gmt] => 2024-11-19 15:46:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4495
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4402
[post_author] => 3
[post_date] => 2024-03-01 12:43:19
[post_date_gmt] => 2024-03-01 17:43:19
[post_content] =>
Still time to register! Registration for the 8th annual Hack@CEWIT will close March 1 at 3pm.
Join hundreds of student hackers at the Center of Excellence in Wireless and Information Technology (CEWIT) for a 40-hour hackathon to learn new skills, make new connections, develop innovative ideas and compete for amazing prizes.
CEWIT will open its doors for the event at 5pm today. Do not miss your opportunity to Unleash Innovation and Transform Tomorrow
All participants must reside in the U.S and be currently registered in a college/university as an undergraduate, graduate, or PhD student.
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
